Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice

Key Points Initial FVIII exposure rate is the strongest predictor of immunogenicity after AAV-FVIII gene therapy in hemophilia A mice. Slower initial FVIII exposure rates evolving to steady-state FVIII levels in the normal or higher range support immune tolerance.